跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PRAXBIND - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PRAXBIND
Authorized
STANDARD
PRAXBIND
boehringer ingelheim (canada) ltd ltee
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
bbaa29beeb4f900b
Company
boehringer ingelheim (canada) ltd ltee
Type
Standard
Approval Details
Approval Id
bbaa29beeb4f900b
Drug Approval Canada Name
PRAXBIND
Product Name
PRAXBIND
Status
Marketed
Status Date
2016-05-24
Original Market Date
2016-05-24
Din
02454343
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
20:28.92
Atc Original
V03AB37 IDARUCIZIMAB
Atc Name
v 03 ab 37
Aig Number
0158090001
Company Name
boehringer ingelheim (canada) ltd ltee
Company Address
5180 South Service Road, Burlington, Ontario, Canada, L7L 5H4
Active Ingredients
IDARUCIZUMAB
50 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
bbaa29beeb4f900b
Type
Standard
Back to Health Canada Approvals